Oxford BioDynamics PLC Publication of Annual Report and Notice of AGM (6492A)
23 January 2020 - 6:00PM
UK Regulatory
TIDMOBD
RNS Number : 6492A
Oxford BioDynamics PLC
23 January 2020
23 January 2020
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Publication of 2019 Annual Report and Accounts and Notice of
AGM
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company
focused on the discovery and development of biomarkers based on
regulatory 3D genome architecture, for use within the
pharmaceutical and biotechnology industry, today announces that
copies of its annual report and accounts for the year ended 30
September 2019 (incorporating the Notice of Annual General Meeting)
("Annual Report") have been posted to shareholders. An electronic
copy of the Annual Report will be available on its website at
www.oxfordbiodynamics.com, within the Investor Relations
section.
Notice of Annual General Meeting
The Company's Annual General Meeting will be held at The
Kloppenberg Room, Cohen Quad, Exeter College, Walton Street,
Oxford, OX1 2HE, on 20 March 2020 at 11.00 am.
-ENDS-
For further details please contact:
Oxford BioDynamics Plc
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Nominated Advisor and Broker
Stephane Auton
Edward Mansfield +44 (0)20 7408 4090
FTI Consulting
Financial Public Relations
Adviser
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for
Enterprise: Innovation. The Queen's Awards for Enterprise are the
most prestigious awards for UK businesses.
The Company is headquartered in the UK and listed on the London
Stock Exchange's AIM under the ticker "OBD". For more information
please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAFLFFDLDIFFII
(END) Dow Jones Newswires
January 23, 2020 02:00 ET (07:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024